5E Advanced Materials Inc (FEAM)
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-10-30
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-10-30
Research Workspace
Put FEAM beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Specialty Chemicals is in recovery. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Net income improves toward less negative than -$12.1 million: Comparison needs review.
View ThesisThis stock is volatile — it swings about 4% on a typical day and fell roughly 79% in its worst 12-month stretch.
View RiskFEAM’s bet is its shift from developer to operating boron producer. Its primary revenue focus is boric acid production. Acquisition and financing support that shift. No earnings release is on record, so recent revenue growth and results remain unverified. A concrete current multiple and peer comparison are unavailable. The desk gives no priced-in expectations reading. The next-quarter miss probability is 30%. The primary net-income comparison needs review, so the claimed progress is unverified. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. FEAM is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 2 analysts currently covering FEAM (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare FEAM with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| FEAM Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Specialty Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put FEAM next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Transform from developer to operating critical minerals producer
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Acquisition and financing support transition to operating producer.

Advances: Focus on boric acid production as primary revenue source
Boron production scaling aligns with revenue focus.

Completion of assessment supports future product development.